Search

Your search keyword '"Baillot-Rudoni S"' showing total 140 results
Start Over Author "Baillot-Rudoni S"
140 results on '"Baillot-Rudoni S"'

11. Treatment with liraglutide leads to an important reduction in liver fat content, assessed by magnetic resonance spectroscopy, in people with type 2 diabetes

Author

Vergès, Bruno, Bouillet, B., Guiu, B., Buffier, P., Baillot-rudoni, S., BRINDISI, Marie-Claude, Crevisy, E., Fourmont, C., Cercueil, J. P., Petit, J., Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CRI 866, Institut National de la Santé et de la Recherche Médicale (INSERM), INRA, Institut National de la Recherche Agronomique (INRA), and NovoNordisk Grant

Subjects
[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background and aims: Most studies found that 60-75% of patients with type 2 diabetes have Non-Alcoholic Fatty Liver Disease. Unfortunately, there is no treatment of NAFLD in people with diabetes besides weight loss and increased physical activity. Some animal studies have shown that GLP-1 receptor agonists may reduce liver lipogenesis. The effect of the GLP-1 receptor agonist, liraglutide on liver fat remain unknown in patients with type 2 diabetes. This prompted us to perform a prospective study on the effect of liraglutide on liver fat content, in type 2 diabetes. Materials and methods: A total of 43 patients with type 2 diabetes mellitus were included in this study. Liver fat was measured by 1H-magnetic resonance spectroscopy (gold-standard method for liver fat measurement) before and after 6 months of liraglutide therapy (1.2 mg/j). Results: Thirty-five (81.3%) patients had steatosis at baseline (hepatic triglyceride content greater than 5.5%). At inclusion, liver fat content was correlated with fasting serum triglycerides (r=0.33; p=0.02) and alanine aminotransferase (ALAT) (r=0.46; p= 0.002). Treatment with liraglutide was associated with a mean weight loss of 4.4 kg (p

Published
2015

12. Decline in renal function was not associated with steatosis evaluated by proton-spectroscopy in a population of people with type 2 diabetes

Author

Petit, Jean-Michel, Fourmont, C., Guiu, B., Bouillet, B., BRINDISI, Marie-Claude, Crevisy, E., Buffier, P., Baillot-rudoni, S., Cercueil, J. P., Vergès, Bruno, ProdInra, Archive Ouverte, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CRI 866, Institut National de la Santé et de la Recherche Médicale (INSERM), INRA, Institut National de la Recherche Agronomique (INRA), and NovoNordisk Grant

Subjects
[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Decline in renal function was not associated with steatosis evaluated by proton-spectroscopy in a population of people with type 2 diabetes J.-M. Petit, C. Fourmont, B. Guiu, B. Bouillet, M.-C. Brindisi, E. Crevisy, P. Buffier, S. Baillot-Rudoni, J. Cercueil, B. Verges; diabetologie, CHU du Bocage, Dijon, France. Background and aims: Data regarding the link between hepatic steatosis and renal function in people with type 2 diabetes are controversial. Liver fat content was associated with the development of diabetic nephropathy in cross-sectional studies but not in one longitudinal study. We aimed to determine whether liver fat content was associated with a decline in renal function in patients with type 2 diabetes. Materials and methods: Two hundred and twenty-three patients with type 2 diabetes were included in the study. Liver fat content was measured by proton spectroscopy at inclusion. Steatosis was defined by liver fat content greater than 5.5%. The decline in renal function was assessed by changes in the estimated glomerular filtration rate (eGFR), (MDRD formula) over time. Diabetic nephropathy at inclusion was defined by the presence of microalbuminuria or macroproteinuria. Results: One hundred and thirty-four (60.1%) patients had steatosis. Those with steatosis had higher BMI (p=0.0003), lower diabetes duration (p=0.005) and a lower frequency of diabetic nephropathy at inclusion (12.6% vs 24.7%, p=0.03). Age, HbA1c and eGFR at inclusion were not statistically different between groups. The median follow up was 4.4 years. Hepatic steatosis was not associated with the rate of decline in renal function calculated by year, but the difference was borderline significant (Patients with steatosis had a lower annual renal decline than those without steatosis (+ 0.48 vs. -0.98 ml/min per year, p=0.06). In multivariate analysis, steatosis was associated with BMI, but not with age, diabetes duration, diabetic nephropathy at inclusion, eGFR at inclusion, renal decline per year or gender. Conclusion: When we used an accurate method to evaluate liver fat content, the presence of steatosis was not associated with the decline in renal function in our cohort of patients with type 2 diabetes. Our study suggests that early identification of hepatic steatosis in people with type 2 diabetes may not be useful to identify people at the highest risk of renal decline.

Published
2015

14. P153 Un IMC, une HbA1c et des γGT élevés sont des facteurs prédictifs d’amélioration glycémique avec le traitement par pompe à insuline chez des patients diabétiques de type 2: suivi bicentrique sur 2 ans

Author

Crevisy, E., primary, Baillot-Rudoni, S., additional, Buffier, P., additional, Beacco, M., additional, Nguyen, A., additional, Fourmont, C., additional, Bouillet, B., additional, Borot, S., additional, Petit, J.-M., additional, Penfornis, A., additional, Vergès, B., additional, and Habchi, M., additional

Published
2015
Full Text
View/download PDF

15. P200 Effet d’un traitement par liraglutide sur le contenu hépatique en graisse de patients diabétiques de type 2: étude prospective par spectroscopie-RMN

Author

Petit, J.-M., primary, Bouillet, B., additional, Guiu, B., additional, Buffier, P., additional, Baillot-Rudoni, S., additional, Brindisi, M.-C., additional, Crevisy, E., additional, Fourmont, C., additional, Simoneau, I., additional, Cercueil, J.-P., additional, and Verges, B., additional

Published
2015
Full Text
View/download PDF

46. Low HDL-cholesterol: A strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes.

Author

Vergès B, Radu L, Baillot-Rudoni S, Brindisi MC, Poussier A, Bouillet B, Petit JM, and Duvillard L

Abstract

We performed a study in 102 people with type 2 diabetes aiming to determine 'easy-to-use' predictive factors for glycemic response to glitazones. We found that low baseline HDL-cholesterol (<40mg/L [1.04mmol/L] in males, <50mg/L [1.30mmol/L] in females) was a strong independent predictor of glycemic response to glitazones (OR=2.67 [2.02-3.52], p=0.0004). [ABSTRACT FROM AUTHOR]

Published
2011

47. Glycemic Variability Assessment with a 14-Day Continuous Glucose Monitoring System: When and How Long to Measure MAGE (Mean Amplitude of Glucose Excursion) for Optimal Reliability?

Author

Vergès B, Pignol E, Rouland A, Bouillet B, Baillot-Rudoni S, Quilot E, Djeffal A, and Petit JM

Subjects
Blood Glucose Self-Monitoring, Glucose, Humans, Reproducibility of Results, Blood Glucose, Diabetes Mellitus, Type 2
Abstract

Mean amplitude of glucose excursion (MAGE) is considered as the "gold standard" for assessing the short-term within-day glycemic variability (GV), which is an important component of overall glycemic control. A 14-day continuous glucose monitoring system is now widely used and allows easier assessment of GV. However, it is still unknown whether MAGE, usually calculated on a 48-hour period is identical whatever the time during the 14-day lifespan of the sensor and whether a longer time period might give additional information. We evaluated in 68 patients with type 1 diabetes, MAGE during three 2-day periods (day1-day3; day6-day8; day11-day13) and during periods of 3 days and 4 days. MAGE calculated at the three 2-day periods were identical and not different from MAGE of the 3-day or 4-day periods.

Published
2022
Full Text
View/download PDF

48. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.

Author

Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Petit JM, Degrace P, and Demizieux L

Subjects
Animals, Humans, Lipoproteins, Lipoproteins, LDL metabolism, Lipoproteins, VLDL metabolism, Liraglutide therapeutic use, Mice, Retinol-Binding Proteins, Plasma, Subtilisins, Diabetes Mellitus, Type 2 drug therapy, Proprotein Convertase 9 genetics
Abstract

Objective: Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins., Research Design and Methods: We performed an in vivo kinetic study with stable isotopes (L-[1- 13 C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-containing lipoprotein clearance., Results: In patients with T2D, liraglutide treatment significantly reduced plasma apoB100 (0.93 ± 0.13 vs. 1.09 ± 0.11 g/L, P = 0.011) and fasting triglycerides (1.76 ± 0.37 vs. 2.48 ± 0.69 mmol/L, P = 0.005). The kinetic study showed a significant increase in indirect catabolism of VLDL 1 -apoB100 (4.11 ± 1.91 vs. 2.96 ± 1.61 pools/day, P = 0.005), VLDL 2 -apoB100 (5.17 ± 2.53 vs. 2.84 ± 1.65 pools/day, P = 0.008), and IDL-apoB100 (5.27 ± 2.77 vs. 3.74 ± 1.85 pools/day, P = 0.017) and in catabolism of LDL-apoB100 (0.72 ± 0.22 vs. 0.56 ± 0.22 pools/day, P = 0.005). In mice, liraglutide increased lipoprotein lipase (LPL) gene expression and reduced proprotein convertase subtilisin/kexin type 9 (PCSK9), retinol-binding protein 4 (RBP4), and tumor necrosis factor-α (TNF-α) gene expression in adipose tissue and decreased PCSK9 mRNA and increased LDL receptor protein expression in liver. In vitro, liraglutide directly reduced the expression of PCSK9 in the liver., Conclusions: Treatment with liraglutide induces a significant acceleration of the catabolism of triglyceride-rich lipoproteins (VLDL 1 , VLDL 2 , IDL) and LDL. Liraglutide modifies the expression of genes involved in apoB100-containing lipoprotein catabolism. These positive effects on lipoprotein metabolism may reduce cardiovascular risk in T2D., (© 2021 by the American Diabetes Association.)

Published
2021
Full Text
View/download PDF

49. Increased body fat mass reduces the association between fructosamine and glycated hemoglobin in obese type 2 diabetes patients.

Author

Vergès B, Rouland A, Baillot-Rudoni S, Brindisi MC, Duvillard L, Simoneau I, Legris P, Petit JM, and Bouillet B

Subjects
Aged, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 diagnostic imaging, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Obesity complications, Obesity diagnostic imaging, Prospective Studies, Abdominal Fat diagnostic imaging, Diabetes Mellitus, Type 2 blood, Fructosamine blood, Glycated Hemoglobin metabolism, Obesity blood
Abstract

Obesity is increasing in patients with type 2 diabetes. A possible reduced association between fructosamine and glycated hemoglobin (HbA1c) in obese individuals has been previously discussed, but this has never been specifically evaluated in type 2 diabetes, and the potential influence of body fat mass and fat distribution has never been studied. We studied 112 type 2 diabetes patients with assessment of fat mass, liver fat and fat distribution. Patients with body mass index (BMI) above the median (34.9 kg/m 2 ), versus BMI below the median, had a correlation coefficient between fructosamine and HbA1c significantly reduced (r = 0.358 vs r = 0.765). In the whole population, fructosamine was correlated negatively with BMI and fat mass. In multivariate analysis, fructosamine was associated with HbA1c (positively) and fat mass (negatively), but not with BMI, liver fat or fat distribution. The association between fructosamine and HbA1c is significantly reduced in the most obese type 2 diabetes patients, and this is mostly driven by increased fat mass., (© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)

Published
2021
Full Text
View/download PDF

50. Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.

Author

Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Sberna AL, Petit JM, Degrace P, and Demizieux L

Subjects
Adipose Tissue metabolism, Animals, Apolipoprotein B-48 drug effects, Apolipoprotein B-48 genetics, Carrier Proteins genetics, Carrier Proteins metabolism, Chylomicrons biosynthesis, Diabetes Mellitus, Type 2 blood, Diacylglycerol O-Acyltransferase genetics, Diacylglycerol O-Acyltransferase metabolism, Female, Gene Expression, Humans, Hyperlipidemias complications, Jejunum metabolism, Lipoprotein Lipase metabolism, Male, Mice, Inbred BALB C, Postprandial Period, Prospective Studies, Triglycerides blood, Apolipoprotein B-48 blood, Diabetes Mellitus, Type 2 complications, Hyperlipidemias blood, Hyperlipidemias drug therapy, Liraglutide therapeutic use
Abstract

Objective- Treatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist, has been shown to reduce postprandial lipidemia, an important feature of diabetic dyslipidemia. However, the underlying mechanisms for this effect remain unknown. This prompted us to study the effect of liraglutide on the metabolism of ApoB48 (apolipoprotein B48). Approach and Results- We performed an in vivo kinetic study with stable isotopes (D 8 -valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d). We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides and analysed in vitro on jejunum, the direct effect of liraglutide on the expression of genes involved in the biosynthesis of chylomicron. In diabetic patients, liraglutide treatment induced a dramatic reduction of ApoB48 pool (65±38 versus 162±87 mg; P=0.005) because of a significant decrease in ApoB48 production rate (3.02±1.33 versus 6.14±4.27 mg kg -1 d -1 ; P=0.009) and a significant increase in ApoB48 fractional catabolic rate (5.12±1.35 versus 3.69±0.75 pool d -1 ; P=0.005). One-week treatment with liraglutide significantly reduced postload plasma triglycerides in mice and liraglutide, in vitro, reduced the expression of ApoB48, DGAT1 (diacylglycerol O-acyltransferase 1), and MTP (microsomal transfer protein) genes. Conclusions- We show that treatment with liraglutide induces a significant reduction of the ApoB48 pool because of both a reduction of ApoB48 production and an increase in ApoB48 catabolism. In vitro, liraglutide reduces the expression of genes involved in chylomicron synthesis. These effects might benefit cardiovascular health. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT02721888.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results